{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T09:13:19Z","timestamp":1764493999505,"version":"3.41.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,12,2]],"date-time":"2017-12-02T00:00:00Z","timestamp":1512172800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nefrolog\u00eda"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.nefro.2017.10.002","type":"journal-article","created":{"date-parts":[[2017,12,24]],"date-time":"2017-12-24T03:51:32Z","timestamp":1514087492000},"page":"258-266","source":"Crossref","is-referenced-by-count":10,"title":["Lipodistrofia parcial adquirida y glomerulopat\u00eda C3: la desregulaci\u00f3n del sistema del complemento como mecanismo com\u00fan"],"prefix":"10.1016","volume":"38","author":[{"given":"Fernando","family":"Corvillo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margarita","family":"L\u00f3pez-Trascasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nefro.2017.10.002_bib0165","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/ni.1923","article-title":"Complement: A key system for immune surveillance and homeostasis","volume":"11","author":"Ricklin","year":"2010","journal-title":"Nat Immunol"},{"key":"10.1016\/j.nefro.2017.10.002_bib0170","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/imr.12466","article-title":"Properdin: A tightly regulated critical inflammatory modulator","volume":"274","author":"Blatt","year":"2016","journal-title":"Immunol Rev"},{"key":"10.1016\/j.nefro.2017.10.002_bib0175","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.it.2012.06.001","article-title":"The complotype: Dictating risk for inflammation and infection","volume":"33","author":"Harris","year":"2012","journal-title":"Trends Immunol"},{"key":"10.1016\/j.nefro.2017.10.002_bib0180","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.2215\/CJN.01710216","article-title":"All Things Complement","volume":"11","author":"Thurman","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2017.10.002_bib0185","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.imlet.2014.01.014","article-title":"Autoantibodies to complement components in C3 glomerulopathy and atypical hemolytic uremic syndrome","volume":"160","author":"J\u00f3zsi","year":"2014","journal-title":"Immunol Lett"},{"key":"10.1016\/j.nefro.2017.10.002_bib0190","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jaci.2017.02.018","article-title":"C3 nephritic factors: A changing landscape","volume":"140","author":"Levy Erez","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.nefro.2017.10.002_bib0195","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1056\/NEJMra025261","article-title":"Acquired and inherited lipodystrophies","volume":"350","author":"Garg","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefro.2017.10.002_bib0200","doi-asserted-by":"crossref","first-page":"8879","DOI":"10.1093\/nar\/14.22.8879","article-title":"Adipsin, the adipocyte serine protease: Gene structure and control of expression by tumor necrosis factor","volume":"14","author":"Min","year":"1986","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.nefro.2017.10.002_bib0205","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1126\/science.3299705","article-title":"Adipsin: A circulating serine protease homolog secreted by adipose tissue and sciatic nerve","volume":"237","author":"Cook","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.nefro.2017.10.002_bib0210","doi-asserted-by":"crossref","first-page":"9210","DOI":"10.1016\/S0021-9258(19)50409-4","article-title":"Human adipsin is identical to complement factor D and is expressed at high levels in adipose tissue","volume":"267","author":"White","year":"1992","journal-title":"J Biol Chem"},{"key":"10.1016\/j.nefro.2017.10.002_bib0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-2249.1997.d01-890.x","article-title":"Extrahepatic complement biosynthesis: Where, when and why?","volume":"107","author":"Morgan","year":"1997","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.nefro.2017.10.002_bib0220","doi-asserted-by":"crossref","first-page":"12736","DOI":"10.1016\/S0021-9258(18)42338-1","article-title":"Adipsin and an endogenous pathway of complement from adipose tissue","volume":"267","author":"Choy","year":"1992","journal-title":"J Biol Chem"},{"key":"10.1016\/j.nefro.2017.10.002_bib0225","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.molimm.2012.02.110","article-title":"A new effector of lipid metabolism: Complement factor properdin","volume":"51","author":"Gauvreau","year":"2012","journal-title":"Mol Immunol"},{"key":"10.1016\/j.nefro.2017.10.002_bib0230","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3109\/07853899409148358","article-title":"The adipsin-ASP pathway and regulation of adipocyte function","volume":"26","author":"Sniderman","year":"1994","journal-title":"Ann Med"},{"key":"10.1016\/j.nefro.2017.10.002_bib0235","doi-asserted-by":"crossref","first-page":"11123","DOI":"10.1074\/jbc.M206169200","article-title":"The chemoattractant receptor-like protein C5L2 binds the C3a des-Arg77\/acylation-stimulating protein","volume":"278","author":"Kalant","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.nefro.2017.10.002_bib0240","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1194\/jlr.M500500-JLR200","article-title":"Targeting the signaling pathway of acylation stimulating protein","volume":"47","author":"Maslowska","year":"2006","journal-title":"J Lipid Res"},{"key":"10.1016\/j.nefro.2017.10.002_bib0245","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.ecl.2017.01.012","article-title":"Genetics of Lipodystrophy","volume":"46","author":"Lightbourne","year":"2017","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.nefro.2017.10.002_bib0250","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.ecl.2016.06.012","article-title":"Lipodystrophy Syndromes","volume":"45","author":"Hussain","year":"2016","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.nefro.2017.10.002_bib0255","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/00000441-188507000-00006","article-title":"Singular case of absence of adipose matter in the upper half of the body","volume":"90","author":"Mitchell","year":"1885","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.nefro.2017.10.002_bib0260","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/01.md.0000111061.69212.59","article-title":"Clinical features and metabolic and autoimmune derangements in acquired partial lipodystrophy: Report of 35 cases and review of the literature","volume":"83","author":"Misra","year":"2004","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.nefro.2017.10.002_bib0265","first-page":"605","article-title":"Chronic renal disease in children with lipodystrophy","volume":"96","author":"Gellis","year":"1958","journal-title":"AMA J Dis Child"},{"key":"10.1016\/j.nefro.2017.10.002_bib0270","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1056\/NEJM197602262940902","article-title":"The complement abnormalities of lipodystrophy","volume":"294","author":"Sissons","year":"1976","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefro.2017.10.002_bib0275","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.nefro.2016.03.003","article-title":"Acquired partial lipodystrophy (Barraquer-Simons syndrome) and IgA nephropathy","volume":"36","author":"de Lucas-Collantes","year":"2016","journal-title":"Nefrologia"},{"key":"10.1016\/j.nefro.2017.10.002_bib0280","first-page":"73","article-title":"Mesangiocapillary glomerulonephritis with dense \u00abdeposits\u00bb in the basement membranes of the kidney","volume":"5","author":"Vargas","year":"1976","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.nefro.2017.10.002_bib0285","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1084\/jem.177.6.1827","article-title":"Complement-mediated adipocyte lysis by nephritic factor sera","volume":"177","author":"Mathieson","year":"1993","journal-title":"J Exp Med"},{"key":"10.1016\/j.nefro.2017.10.002_bib0290","first-page":"564","article-title":"Partial lipodystrophy in two HLA identical sisters with hypocomplementemia and nephropathy","volume":"22","author":"Peces","year":"2002","journal-title":"Nefrologia"},{"key":"10.1016\/j.nefro.2017.10.002_bib0295","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1681\/ASN.2013070732","article-title":"Characterization of a factor H mutation that perturbs the alternative pathway of complement in a family with membranoproliferative GN","volume":"25","author":"Wong","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2017.10.002_bib0300","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1086\/505885","article-title":"Sequencing of the reannotated LMNB2 gene reveals novel mutations in patients with acquired partial lipodystrophy","volume":"79","author":"Hegele","year":"2006","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.nefro.2017.10.002_bib0305","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1210\/jc.2016-2466","article-title":"The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline","volume":"101","author":"Brown","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.nefro.2017.10.002_bib0310","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2016-216134","article-title":"Barraquer-Simons syndrome: a unique patient's perspective on diagnosis, disease progression and recontouring treatment","volume":"2016","author":"Heidemann","year":"2016","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.nefro.2017.10.002_bib0315","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.molimm.2017.05.013","article-title":"Complement in clinical medicine: Clinical trials, case reports and therapy monitoring","volume":"89","author":"Ricklin","year":"2017","journal-title":"Mol Immunol"},{"key":"10.1016\/j.nefro.2017.10.002_bib0320","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1007\/s00467-013-2748-5","article-title":"Eculizumab therapy in a patient with dense-deposit disease associated with partial lipodystropy","volume":"29","author":"Ozkaya","year":"2014","journal-title":"Pediatr Nephrol"}],"container-title":["Nefrolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0211699517302278?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0211699517302278?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,29]],"date-time":"2025-06-29T04:50:32Z","timestamp":1751172632000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0211699517302278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S0211699517302278"],"URL":"https:\/\/doi.org\/10.1016\/j.nefro.2017.10.002","relation":{},"ISSN":["0211-6995"],"issn-type":[{"type":"print","value":"0211-6995"}],"subject":[],"published":{"date-parts":[[2018,5]]}}}